Gary Raskob to Administration, Oral
This is a "connection" page, showing publications Gary Raskob has written about Administration, Oral.
Connection Strength
1.406
-
Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16.
Score: 0.178
-
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.
Score: 0.155
-
Edoxaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 07 05; 379(1):95-96.
Score: 0.150
-
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30.
Score: 0.113
-
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
Score: 0.106
-
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64.
Score: 0.096
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
Score: 0.086
-
Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
Score: 0.047
-
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 10; 174(10):1420-1429.
Score: 0.047
-
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60.
Score: 0.047
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
Score: 0.039
-
Oral anticoagulant therapy. Curr Opin Hematol. 1996 Sep; 3(5):361-4.
Score: 0.033
-
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 07 04; 116(1):155-61.
Score: 0.032
-
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
Score: 0.027
-
Long-term oral anticoagulant therapy for coronary artery disease. Haemostasis. 1993 Mar; 23 Suppl 1:32-41.
Score: 0.026
-
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51.
Score: 0.026
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04 05; 366(14):1287-97.
Score: 0.024
-
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
Score: 0.022
-
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
Score: 0.022
-
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
Score: 0.022
-
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15.
Score: 0.021
-
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3.
Score: 0.020
-
Anticoagulant therapy for venous thromboembolism. Prog Hemost Thromb. 1989; 9:1-27.
Score: 0.019
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
Score: 0.018
-
Hemorrhagic complications of anticoagulant treatment. Chest. 1998 Nov; 114(5 Suppl):511S-523S.
Score: 0.010
-
Hemorrhagic complications of anticoagulant treatment. Chest. 1995 Oct; 108(4 Suppl):276S-290S.
Score: 0.008
-
A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6.
Score: 0.007
-
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81.
Score: 0.003